
BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target
BioCryst Pharmaceuticals (BCRX) Analyst Ratings
Bulls say
BioCryst Pharmaceuticals Inc. has experienced a notable increase in sales, reaching 13.9% of global revenues in the fourth quarter of 2024, up from 11.4% in the previous quarter, signaling robust growth momentum. The company's flagship product, Orladeyo, is gaining traction among physicians, with 59% now extremely likely to prescribe it, reflecting a 26% increase compared to early 2023, which bodes well for future revenue. Furthermore, with projected Orladeyo revenue guidance for 2025 raised to $535M-$550M, alongside a broader total revenue forecast increase, BioCryst is well-positioned to reach its ambitious target of $1B in peak global sales by 2029, underpinned by its product's efficacy and improved reimbursement conditions.
Bears say
BioCryst Pharmaceuticals Inc. is facing significant challenges that contribute to a negative financial outlook, including a forecast of flat to lower sales for Orladeyo in 1Q24, primarily due to the substantial reauthorization process affecting approximately 50% of patients. The company has consistently reported losses since its inception, with a notable net loss of $26.8 million for 4Q24, raising concerns about its pathway to profitability, which is still likely several years away. Additionally, operational expenses exceeded market expectations in 4Q24, driven by higher-than-expected selling, general, and administrative costs, further complicating the company's financial stability.
This aggregate rating is based on analysts' research of BioCryst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
BioCryst Pharmaceuticals (BCRX) Analyst Forecast & Price Prediction
Start investing in BioCryst Pharmaceuticals (BCRX)
Order type
Buy in
Order amount
Est. shares
0 shares